Cargando…
Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011266/ https://www.ncbi.nlm.nih.gov/pubmed/36495403 http://dx.doi.org/10.1007/s40744-022-00514-0 |
| _version_ | 1784906351851339776 |
|---|---|
| author | Lubrano, Ennio Scriffignano, Silvia Perrotta, Fabio Massimo |
| author_facet | Lubrano, Ennio Scriffignano, Silvia Perrotta, Fabio Massimo |
| author_sort | Lubrano, Ennio |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10011266 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Healthcare |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100112662023-03-15 Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective Lubrano, Ennio Scriffignano, Silvia Perrotta, Fabio Massimo Rheumatol Ther Commentary Springer Healthcare 2022-12-10 /pmc/articles/PMC10011266/ /pubmed/36495403 http://dx.doi.org/10.1007/s40744-022-00514-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Commentary Lubrano, Ennio Scriffignano, Silvia Perrotta, Fabio Massimo Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective |
| title | Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective |
| title_full | Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective |
| title_fullStr | Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective |
| title_full_unstemmed | Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective |
| title_short | Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective |
| title_sort | sequencing of biologic and target synthetic disease-modifying anti-rheumatic drugs in psoriatic arthritis: are we ready to redefine the treatment strategy? a perspective |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011266/ https://www.ncbi.nlm.nih.gov/pubmed/36495403 http://dx.doi.org/10.1007/s40744-022-00514-0 |
| work_keys_str_mv | AT lubranoennio sequencingofbiologicandtargetsyntheticdiseasemodifyingantirheumaticdrugsinpsoriaticarthritisarewereadytoredefinethetreatmentstrategyaperspective AT scriffignanosilvia sequencingofbiologicandtargetsyntheticdiseasemodifyingantirheumaticdrugsinpsoriaticarthritisarewereadytoredefinethetreatmentstrategyaperspective AT perrottafabiomassimo sequencingofbiologicandtargetsyntheticdiseasemodifyingantirheumaticdrugsinpsoriaticarthritisarewereadytoredefinethetreatmentstrategyaperspective |